In patients with type 2 diabetes mellitus (T2DM), the concurrent use of warfarin and sulphonylureas was associated with an increased risk of hypoglycaemia. There was no significant association between ...

There are several drugs that are being used for treatment of type 2 diabetes. Many type 2 diabetics suffer from kidney disorders that are caused by persistent high levels of blood sugar. The number of ...

New research shows that concomitant use of dipeptidyl peptidase 4 (DPP-4) inhibitors and sulphonylureas increases the risk of hypoglycaemia in patients with type 2 diabetes mellitus (T2DM). The ...

A study of nurses with diabetes in the US shows that long term use of sulphonylureas could increase the risk of coronary heart disease. Sulphonylureas are a widely prescribed class of drug for ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

In patients with type 2 diabetes (T2D) with and without major adverse cardiovascular events (MACE), those who initiated dipeptidyl-peptidase-4 inhibitors (DPP-4i) as an add-on treatment to metformin ...

Sulphonylureas, a type of drug widely used to treat type 2 diabetes, carries a greater risk of heart failure and death compared with metformin, another popular anti-diabetes drug. Sulphonylureas, a ...

Monotherapy for type two diabetes patients with most sulphonylureas has a higher risk of all-cause and cardiovascular death compared with metformin, say researchers. Compared to metformin, patients ...

Sulphonylureas, a type of drug widely used to treat type 2 diabetes, has a greater risk of causing heart failure and death as compared to metformin, another popular antidiabetes drug, according to a ...

GPs should consider alternatives to sulphonylureas in patients with Type 2 diabetes as their use is linked to an increase in cardiovascular disease, claim researchers. The US meta-analysis of 33 ...